May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
32 citations
,
April 2019 in “JAAD case reports” JAK inhibitors helped treat hair loss in two people with Down syndrome.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
November 2023 in “Research Portal Denmark” Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
April 2026 in “Laboratory Animal Research” The new Hairless R/J mice model improves imaging for tumor monitoring and cancer therapy evaluation.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
2 citations
,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
Frontal fibrosing alopecia can be managed with personalized combination therapies, but no cure exists yet.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
March 2025 in “Experimental Dermatology” Overexpression of IKZF1 and Ikaros causes hair loss in mice similar to alopecia areata.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Too much IKZF1 and Ikaros protein may cause alopecia areata.
May 2026 in “Inflammopharmacology” October 2023 in “The Open Dermatology Journal” Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
April 2024 in “Journal of clinical medicine” Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
1 citations
,
March 2025 in “JAAD reviews.” Significant progress has been made in treating skin, hair, and nail disorders in people with skin of color, but disparities still exist.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
1 citations
,
June 2025 in “Journal of Patient Experience” Alopecia areata greatly affects quality of life, with many experiencing mental health issues and lacking professional support.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
5 citations
,
April 2019 in “Journal of Investigative Dermatology” Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.